WHO Bulletin Article On Local Pharmaceutical Manufacturing In Africa 03/03/2014 by Intellectual Property Watch Leave a Comment An article published in the March 2014 issue of the World Health Organisation Bulletin discusses the evolving issue of access to medicines in Africa.
TRIPS Council: Discussion Of IP And Innovation Irritates India: Other Issues Unchanged 27/02/2014 by Catherine Saez, Intellectual Property Watch 1 Comment World Trade Organization members at the WTO intellectual property committee this week held fast to positions on longstanding issues, but engaged in discussions on issues such as innovation in relation to universities, and so-called “non-violation complaints” against countries that may cause harm to another country but don’t violate a WTO rule. Also discussed was the ongoing dispute over plain packaging requirements for tobacco products.
IP Rights Impact Practice Of Science, Global Justice, Author Says 26/02/2014 by Intellectual Property Watch Leave a Comment Intellectual property has a strong effect on the practice of science, leading to a shift in research attention for the benefit of the rich, while impeding access to essential goods for the disadvantaged, according to a recent book.
US Congress Committee Issues Report On “Highly Invasive” FDA Surveillance Of Employees 26/02/2014 by Intellectual Property Watch Leave a Comment The United States House of Representatives Committee on Oversight and Government Reform today released a report detailing the US Food and Drug Administration’s “highly-invasive” surveillance programme that monitored employees who contacted Congress and the media, according to a press release from the committee leaders. Surveillance was unauthorised and whistleblowers were not given sufficient protection, the report found.
UNITAID Assesses Potential Implications Of Trans-Pacific Partnership Agreement 26/02/2014 by Julia Fraser for Intellectual Property Watch 2 Comments UNITAID is expected to soon publish a report on the implications of the leaked provisions of the Trans-Pacific Partnership agreement (TPP) on public health and access to medicines.
EU Trademark Reform Delayed; Debate Includes Goods-In-Transit, Harmonisation 25/02/2014 by Dugie Standeford for Intellectual Property Watch Leave a Comment Efforts to update European Union trademark law have slowed amid political differences and squabbles over some provisions of the reform package, representatives from the European Commission (EC), European Parliament and trademark community say. Contrary to the wishes of the EC and lawmakers, the legislation will not be completed before European parliamentary elections in May.
Year Ahead: Biotech, IP Promise to Create Controversy From Farms To Big Pharma In 2014 25/02/2014 by Liza Porteus Viana, Intellectual Property Watch 1 Comment The intersection of biotechnology and intellectual property continues to be a hot topic across the globe. From the patenting of certain plant varieties to human genes, to biodiversity and food security, to genetic resources, countries from developing to developed are attempting to navigate often blurred lines in terms of what can and cannot be patented, what should – and shouldn’t – be patented, and protecting innovators from farmers to plant breeders to drug manufacturers.
Infojustice: Graphics Show Rise In US Pharma Exports To India, Patent Grants By India 24/02/2014 by Intellectual Property Watch Leave a Comment Mike Palmedo at Infojustice.org writes: “The U.S. International Trade Commission (ITC) is currently investigating “Indian industrial policies that discriminate against U.S. imports… and the effect those barriers have on the U.S. economy and U.S. jobs.” The investigation was requested by Sen. Hatch, Sen. Baucus, Rep. Camp, and Rep. Levin, and the final report is due to be released in November. Last week it held a series of hearings, where it heard from U.S. business, Indian business, and civil society representatives.”
Interview With Nazeem Mohamed, CEO Of Kampala Pharmaceutical Industries 20/02/2014 by Catherine Saez, Intellectual Property Watch Leave a Comment Nazeem Mohamed is chief executive officer of Kampala Pharmaceutical Industries (KPI), a Ugandan generic manufacturer. Local manufacture of medicines is described by many, including the World Health Organization, as one of the tools that will increase access to medicines. Mohamed is former vice-president of strategic product development at Novo Nordisk, based in Belgium. He also worked for several leading multinational companies such as Pfizer and GlaxoSmithKline before his appointment as CEO of KPI. With Intellectual Property Watch, Mohamed discussed KPI, the challenges of local drug production, the burden of non-communicable diseases, the issue of substandard medicines, rules engineered in the West which can hinder affordability and access in a least-developed country, unfair competition, and unmet skills building needs.
TTIP: No Lowering Of Standards, Officials Say; New Trade Consultation Body Scrutinised 20/02/2014 by Monika Ermert for Intellectual Property Watch Leave a Comment After three rounds of negotiations for the Transatlantic Trade and Investment Partnership (TTIP), European Union Trade Commissioner Karel de Gucht this week welcomed the progress so far. But negotiators have to “step up a gear,” de Gucht said after a two-day stocktaking meeting with the United States Trade Representative Michael Froman in Washington, DC on 18 February. Meanwhile, USTR announced new steps to raise public participation in trade negotiations.